Clinical Trials for Recurrent Diffuse Large B-Cell Lymphoma

Find clinical trials for recurrent diffuse large b-cell lymphoma. Discover research opportunities and treatment options in your area.

22 Active Trials Found

Showing 22 trials on this page

Page 1 of 2

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

NCT ID: NCT06784726

This clinical trial is studying a new treatment called odronextamab for patients with certain types of large B-cell lymphomas that have come back after treatment or did not respond to previous ther...

Recruiting

Phase: PHASE2 Type: interventional Locations: Seattle, Washington, United States

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT ID: NCT05272384

This clinical trial is studying a new treatment for patients with certain types of B-cell lymphoma, specifically those whose cancer has returned after treatment or who have not responded to previou...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States, Birmingham, Alabama, United States +8 more

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT ID: NCT05672251

This clinical trial is exploring a new treatment approach for patients with certain types of aggressive lymphoma, specifically diffuse large B-cell lymphoma that has come back after previous treatm...

Recruiting

Phase: PHASE2 Type: interventional Locations: Duarte, California, United States

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT ID: NCT06649812

This clinical trial, called ViPOR, is exploring a new combination of treatments for patients with aggressive types of B-cell lymphoma that have either come back after treatment (relapsed) or have n...

Not yet recruiting

Phase: PHASE2 Type: interventional

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT ID: NCT06536049

This clinical trial is studying a new treatment option for patients with aggressive types of B-cell non-Hodgkin lymphoma that have either come back after previous treatments or did not respond to t...

Recruiting

Phase: PHASE1 Type: interventional Locations: Minneapolis, Minnesota, United States, Columbus, Ohio, United States

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

NCT ID: NCT05453396

This clinical trial is studying a new treatment called loncastuximab tesirine for patients with specific types of B-cell cancers that have either come back after previous treatments or did not resp...

Recruiting

Phase: PHASE2 Type: interventional Locations: Seattle, Washington, United States

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

NCT ID: NCT06905509

This clinical trial is looking at a new treatment approach for patients with large B-cell lymphoma (LBCL) that has either come back after treatment (relapsed) or did not respond to previous therapi...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Sacramento, California, United States

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT ID: NCT06859008

This clinical trial is studying the combination of two medications, zanubrutinib and sonrotoclax, to treat patients from underrepresented racial and ethnic backgrounds who have a type of blood canc...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

NCT ID: NCT06854159

This clinical trial is studying a new treatment called odronextamab for patients with a type of blood cancer known as diffuse large B-cell lymphoma (DLBCL) that has either returned after previous t...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Sacramento, California, United States

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT ID: NCT05432635

This clinical trial is exploring a new treatment approach for patients with intermediate or high-grade B-cell non-Hodgkin lymphoma, which is a type of cancer affecting the lymphatic system. The stu...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT ID: NCT03418038

This clinical trial is studying the combined effect of ascorbic acid (a form of vitamin C) and chemotherapy on patients with certain types of lymphoma that have either come back after treatment or ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Scottsdale, Arizona, United States, Iowa City, Iowa, United States +5 more

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

NCT ID: NCT05359211

This clinical trial is looking at a new treatment approach for patients with certain types of large B-cell lymphoma, a form of blood cancer that has either come back after treatment or has not resp...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT ID: NCT05633615

This clinical trial is investigating whether two drugs, mosunetuzumab and polatuzumab vedotin, can improve treatment outcomes for patients with certain types of lymphoma, specifically those with di...

Recruiting

Phase: PHASE2 Type: interventional Locations: Durham, North Carolina, United States, Cleveland, Ohio, United States +80 more

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma

NCT ID: NCT04205838

This clinical trial is studying how well a medication called anakinra can help prevent a serious condition called chimeric antigen receptor T-cell-related encephalopathy syndrome (CART-ES) in patie...

Recruiting

Phase: PHASE2 Type: interventional Locations: Los Angeles, California, United States, Davis, California, United States

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NCT ID: NCT05077527

This clinical trial is studying a new treatment called CAR-T therapy, specifically axicabtagene ciloleucel, for patients who have aggressive types of B-cell non-Hodgkin lymphoma related to HIV. The...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chicago, Illinois, United States, New York, New York, United States

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

NCT ID: NCT05800405

This clinical trial is looking at a new way to help patients with a type of cancer called large B-cell lymphoma that has either come back after treatment or did not respond to earlier therapies. Th...

Recruiting

Phase: EARLY_PHASE1 Type: interventional Locations: Duarte, California, United States

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

NCT ID: NCT05890352

This clinical trial is exploring new ways to treat large B-cell lymphoma that has come back or did not respond to previous treatments. Researchers are studying how well a combination of four medica...

Recruiting

Phase: PHASE2 Type: interventional Locations: New York, New York, United States, Ann Arbor, Michigan, United States +10 more

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

NCT ID: NCT06047197

This clinical trial is investigating a new treatment called RC19D2 cell injection for patients with recurrent or refractory diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. The goal o...

Recruiting

Phase: PHASE1 Type: interventional Locations: Tianjin, Tianjin, China

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT ID: NCT06191887

This clinical trial is investigating a new treatment approach for patients with certain types of blood cancers that have returned after treatment or have not responded well to previous therapies. T...

Recruiting

Phase: PHASE1 Type: interventional Locations: Jacksonville, Florida, United States

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT ID: NCT05052528

This clinical trial is studying a new treatment approach for patients with diffuse large B-cell lymphoma that has either returned after previous treatment (relapsed) or did not respond to earlier t...

Recruiting

Phase: PHASE1 Type: interventional Locations: Sacramento, California, United States

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions